Article Type
Changed
Sat, 11/26/2022 - 14:59

Key clinical point: This meta-analysis demonstrated that the elevated pretreatment neutrophil-to-lymphocyte ratio (NLR) was correlated with poor long-term survival in patients with colorectal cancer (CRC) liver metastasis, including those who underwent surgery.

 

Major finding: Higher NLR was associated with poor overall survival (OS; hazard ratio [HR] 1.95; P < .01) and disease-free survival (DFS; HR 1.80; P < .01), and normal vs elevated NLR was associated with a better OS among patients who underwent surgery (HR 1.95; P < .01). The 5-year OS and DFS rates were higher in patients with normal vs high NLR (both P < .01).

 

Study details: The data come from a meta-analysis of 14 retrospective studies including 2974 participants.

 

Disclosures: This study was supported by the Startup Fund for Scientific Research, Fujian Medical University, China. No conflicts of interest were declared.

 

Source: Lin N et al. Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: A meta-analysis of results from multivariate analysis. Int J Surg. 2022;107:106959 (Oct 17). Doi: 10.1016/j.ijsu.2022.106959

Publications
Topics
Sections

Key clinical point: This meta-analysis demonstrated that the elevated pretreatment neutrophil-to-lymphocyte ratio (NLR) was correlated with poor long-term survival in patients with colorectal cancer (CRC) liver metastasis, including those who underwent surgery.

 

Major finding: Higher NLR was associated with poor overall survival (OS; hazard ratio [HR] 1.95; P < .01) and disease-free survival (DFS; HR 1.80; P < .01), and normal vs elevated NLR was associated with a better OS among patients who underwent surgery (HR 1.95; P < .01). The 5-year OS and DFS rates were higher in patients with normal vs high NLR (both P < .01).

 

Study details: The data come from a meta-analysis of 14 retrospective studies including 2974 participants.

 

Disclosures: This study was supported by the Startup Fund for Scientific Research, Fujian Medical University, China. No conflicts of interest were declared.

 

Source: Lin N et al. Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: A meta-analysis of results from multivariate analysis. Int J Surg. 2022;107:106959 (Oct 17). Doi: 10.1016/j.ijsu.2022.106959

Key clinical point: This meta-analysis demonstrated that the elevated pretreatment neutrophil-to-lymphocyte ratio (NLR) was correlated with poor long-term survival in patients with colorectal cancer (CRC) liver metastasis, including those who underwent surgery.

 

Major finding: Higher NLR was associated with poor overall survival (OS; hazard ratio [HR] 1.95; P < .01) and disease-free survival (DFS; HR 1.80; P < .01), and normal vs elevated NLR was associated with a better OS among patients who underwent surgery (HR 1.95; P < .01). The 5-year OS and DFS rates were higher in patients with normal vs high NLR (both P < .01).

 

Study details: The data come from a meta-analysis of 14 retrospective studies including 2974 participants.

 

Disclosures: This study was supported by the Startup Fund for Scientific Research, Fujian Medical University, China. No conflicts of interest were declared.

 

Source: Lin N et al. Prognostic value of neutrophil-to-lymphocyte ratio in colorectal cancer liver metastasis: A meta-analysis of results from multivariate analysis. Int J Surg. 2022;107:106959 (Oct 17). Doi: 10.1016/j.ijsu.2022.106959

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan: Colorectal Cancer, December 2022
Gate On Date
Wed, 06/22/2022 - 11:15
Un-Gate On Date
Wed, 06/22/2022 - 11:15
Use ProPublica
CFC Schedule Remove Status
Wed, 06/22/2022 - 11:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article